8-K Announcements
6Material company update
May 19, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
May 7, 2026·SEC
GeoVax Labs, Inc.(GOVX)Earnings, Financials & Key Ratios
GOVX•NASDAQ
$1.19
Price updated Jul 7, 2026
AboutGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.Show more
- Revenue$2M-37.1%
- EBITDA-$22M+13.6%
- Net Income-$21M+14.1%
- EPS (Diluted)-22.40+81.4%
- Gross Margin100%+2.5%
- EBITDA Margin-869.34%-37.2%
- Operating Margin-869.34%-36.7%
- Net Margin-862.34%-36.4%
- ROE-0%+100.0%
GOVX Price & Volume
GeoVax Labs, Inc. (GOVX) stock price & volume — 10-year historical chart
Loading chart...
Persistent Cash Burn Threatens Clinical Development Continuity
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Insufficient liquidity for operations
Key Thesis Takeaways
- GeoVax Labs faces a precarious outlook as its reliance on volatile, non-recurring grant revenue has led to a complete cessation of income in recent quarters.
- The company's heavy fixed-cost structure, characterized by quarterly R&D expenditures often exceeding $5 million, continues to erode its limited capital base.
- Investors should monitor the critical liquidity position, as the current cash balance of $1.3 million against significant operating losses suggests an imminent requirement for dilutive financing to maintain ongoing clinical operations.
Verdict Logic
the company's cash reserves of only $1.3 million against quarterly operating losses of $5.3 million suggest an unsustainable financial trajectory that necessitates immediate and likely dilutive capital raises.
GOVX Growth Metrics
GeoVax Labs, Inc. (GOVX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years19.25%
5 Years6.42%
3 Years212.55%
TTM-84.76%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM12.78%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM79.01%
Return on Capital
10 Years-210.54%
5 Years-190.13%
3 Years-210.13%
Last Year-0%
Peers Comparison
Key metrics vs top competitors for GeoVax Labs, Inc. (GOVX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.19 | $1.14M | -0.05 | -37.06% | -862.34% | -0% | — | |
| $9.46 | $1.56B | 3.72 | 64.69% | -14.73% | — | — | |
| $4.35 | $1.56B | -3.99 | 60.6% | -123.9% | -50.17% | — | |
| $15.50 | $1.82B | 77.50 | 19.36% | -13.13% | -8.13% | — | |
| $3.67 | $263.23M | 11.12 | -31.8% | 21.61% | 10.62% | — | |
| $3.50 | $145.75M | -1029.41 | 10.37% | 52.16% | — | — |
Compare GOVX vs Peers
GeoVax Labs, Inc. (GOVX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GOVX SEC Filings & Documents
GeoVax Labs, Inc. (GOVX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when GOVX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GOVX Frequently Asked Questions
GeoVax Labs, Inc. (GOVX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is GeoVax Labs, Inc.'s revenue?
GeoVax Labs, Inc. (GOVX) reported $0.9M in revenue for fiscal year 2025. This represents a 807% increase from $0.1M in 1996.
How fast is GeoVax Labs, Inc. growing?
GeoVax Labs, Inc. (GOVX) saw revenue decline by 37.1% over the past year.
Is GOVX profitable?
GeoVax Labs, Inc. (GOVX) reported a net loss of $21.4M for fiscal year 2025.
Dividend & Returns
What is GOVX's return on equity?
GeoVax Labs, Inc. (GOVX) has a return on equity (ROE) of -0.0%. Negative ROE indicates the company is unprofitable.
What is GeoVax Labs, Inc.'s free cash flow?
GeoVax Labs, Inc. (GOVX) had negative free cash flow of $19.0M in fiscal year 2025, likely due to heavy capital investments.